Yiannis Philippou

ORCID: 0000-0002-5335-5871
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Bladder and Urothelial Cancer Treatments
  • Cancer-related molecular mechanisms research
  • Sexual function and dysfunction studies
  • Genital Health and Disease
  • Cancer Immunotherapy and Biomarkers
  • Radiomics and Machine Learning in Medical Imaging
  • Urologic and reproductive health conditions
  • Advanced Radiotherapy Techniques
  • Radiopharmaceutical Chemistry and Applications
  • Molecular Biology Techniques and Applications
  • Hormonal and reproductive studies
  • Urological Disorders and Treatments
  • Cancer, Hypoxia, and Metabolism
  • Urinary Bladder and Prostate Research
  • Cardiac, Anesthesia and Surgical Outcomes
  • Surgical Simulation and Training
  • Health and Medical Research Impacts
  • Environmental Philosophy and Ethics
  • RNA Research and Splicing
  • Effects of Radiation Exposure
  • Diphtheria, Corynebacterium, and Tetanus
  • Renal cell carcinoma treatment
  • Artificial Intelligence in Healthcare and Education

Oxford University Hospitals NHS Trust
2018-2024

John Radcliffe Hospital
2016-2022

University of Oxford
2016-2022

Churchill Hospital
2018-2021

CRUK/MRC Oxford Institute for Radiation Oncology
2018-2020

Nuffield Orthopaedic Centre
2018

Basildon and Thurrock University Hospitals NHS Foundation Trust
2015

East Surrey Hospital
2013-2014

Addenbrooke's Hospital
2013

University of Cambridge
2013

To update, clarify, and extend IDEAL concepts recommendations.New surgical procedures, devices, other complex interventions need robust evaluation for safety, efficacy, effectiveness. Unlike new medicines, there is no internationally agreed pathway generating analyzing data throughout the life cycle of innovations. The Framework Recommendations were designed to provide this they have been used increasingly since their introduction in 2009. Based on a Delphi survey, expert workshop major...

10.1097/sla.0000000000002794 article EN Annals of Surgery 2018-04-24

Radiotherapy enhances innate and adaptive anti-tumour immunity. It is unclear whether this effect may be harnessed by combining immunotherapy with radiotherapy fractions used to treat prostate cancer. We investigated tumour immune microenvironment responses of pre-clinical cancer models radiotherapy. Having defined landscape, we tested radiotherapy-induced growth delay could enhanced anti-PD-L1.

10.1038/s41416-020-0956-x article EN cc-by British Journal of Cancer 2020-07-08

Abstract Background miR-346 was identified as an activator of Androgen Receptor (AR) signalling that associates with DNA damage response (DDR)-linked transcripts in prostate cancer (PC). We sought to delineate the impact on damage, and its potential a therapeutic agent. Methods RNA-IP, RNA-seq, RNA-ISH, fibre assays, vivo xenograft studies bioinformatics approaches were used alongside novel method for amplification-free, single nucleotide-resolution genome-wide mapping breaks (INDUCE-seq)....

10.1186/s12943-022-01540-w article EN cc-by Molecular Cancer 2022-03-22

Objectives To determine whether replacement of protocol‐driven repeat prostate biopsy ( PB ) with multiparametric magnetic resonance imaging (mp MRI ± targeted TB when evaluating men on active surveillance AS for low‐volume, low‐ to intermediate‐risk cancer PC a) altered the likelihood or time treatment, reduced number biopsies required trigger treatment. Patients and Methods A total 445 patients underwent in period 2010–2016 at our institution, a median (interquartile range [ IQR ])...

10.1111/bju.14248 article EN BJU International 2018-04-12

Active surveillance is considered a mainstream strategy in the management of patients with low-risk prostate cancer. A mission-critical step implementing robust active program and plan its resource service requirements, to gauge current practice across United Kingdom. Furthermore it imperative determine existing practices context recommendations suggested by recent National Institute for Health Clinical Excellence guidance on An internet questionnaire was circulated urologists, clinical...

10.1186/s12894-015-0049-y article EN cc-by BMC Urology 2015-06-12

There is a need to improve the treatment of prostate cancer (PCa) and reduce side effects. Vascular-targeted photodynamic therapy (VTP) focal for low-risk low-volume localised PCa, which rapidly disrupts targeted tumour vessels. interest in expanding use VTP higher-risk disease. Tumour vasculature characterised by vessel immaturity, increased permeability, aberrant branching inefficient flow. FRT alters microenvironment promotes transient 'vascular normalisation'. We hypothesised that...

10.1038/s41416-021-01450-6 article EN cc-by British Journal of Cancer 2021-06-21

Abstract Background It is important to identify molecular features that improve prostate cancer (PCa) risk stratification before radical treatment with curative intent. Molecular analysis of historical diagnostic formalin‐fixed paraffin‐embedded (FFPE) biopsies from cohorts post‐radiotherapy (RT) long‐term clinical follow‐up has been limited. Utilizing parallel sequencing modalities, we performed a proof‐of‐principle FFPE biopsies. We compared patients (i) stable PCa (sPCa) postprimary or...

10.1002/pros.24715 article EN cc-by The Prostate 2024-04-23

We report the case of a previously healthy, immunocompetent 23-year-old male who presented to Emergency Department with general malaise, difficulty in breathing, fever, and chest pain. He reported two-week history progressively worsening sore throat that he presumed be viral infection thus initially neglected. However, when his condition deteriorated, was admitted hospital acutely unwell respiratory distress. quickly developed septic shock requiring intensive care admission for inotropic...

10.1155/2015/846715 article EN cc-by Case Reports in Medicine 2015-01-01
Coming Soon ...